---
category: news
title: "Sinaptica’s SinaptiStim – AD Systems Receives Breakthrough Device Status"
excerpt: "The FDA has granted Sinaptica Therapeutics a Breakthrough Device designation for its SinaptiStim – AD System, an electromagnetic therapy for cognitive and functional decline in Alzheimer’s disease patients."
publishedDateTime: 2022-10-20T21:36:00Z
originalUrl: "https://www.fdanews.com/articles/209882-sinapticas-sinaptistim-ad-systems-receives-breakthrough-device-status"
webUrl: "https://www.fdanews.com/articles/209882-sinapticas-sinaptistim-ad-systems-receives-breakthrough-device-status"
type: article
quality: 3
heat: -1
published: false

provider:
  name: FDAnews
  domain: fdanews.com

topics:
  - AI in Healthcare
  - AI

related:
  - title: "FDA breakthrough device designation stimulates increased interest in Sinaptica"
    excerpt: "Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough device designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, brain wave monitoring and artificial intelligence (AI) to address the cognitive and functional decline in patients with the neurological disorder."
    publishedDateTime: 2022-10-19T23:07:00Z
    webUrl: "https://www.bioworld.com/articles/690838-fda-breakthrough-device-designation-stimulates-increased-interest-in-sinaptica"
    type: article
    provider:
      name: BioWorld
      domain: bioworld.com
    quality: 20
    images:
      - url: "https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-construction-blocks.png?height=635&t=1620679875&width=1200"
        width: 847
        height: 635
        isCached: true
  - title: "Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer's Disease"
    excerpt: "Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized electromagnetic therapeutics to treat neurodegenerative diseases, today announced the U.S."
    publishedDateTime: 2022-10-19T13:03:00Z
    webUrl: "https://www.tmcnet.com/usubmit/-sinaptica-therapeutics-announces-fda-breakthrough-device-designation-its-/2022/10/19/9695462.htm"
    type: article
    provider:
      name: TMCnet
      domain: tmcnet.com
    quality: 0
    images:
      - url: "https://images.tmcnet.com/webinars/letthegeekspeak/letthegeekspeak_logo.jpg"
        width: 476
        height: 210
        isCached: true

secured: "5obiUKNgFFlwk6EUIhjw0yc3v6K3M6eBi8zFdi84V1/PZFrTWG0d43uYdvE5lFp4QYDoIkNUfCEO4xo1HBXBlBGw4+GSeKZthfijGtKi1R9xdGhk4wpBNQQj9zBATrGs8cV3XLU8fmougkGPa9F9f/97K+wH0Osd9DY0jiNqrbPVzYXtvrRaeiBlEPZbqlk9riqXKxIHocdMHc6egExD0Yq9I4QYVmpw8NU1KZisU285bu9vHZWNx8wZk0Y8rH8NcPDc55ldntxa9rOCcRHPkKHwjoWuLxq2X+XxgGiw2tY8kL6krLsApJniXoJdznai+AYu6v0LDoXzflj7YQn1HThhYeiUrap1n6tQ/KYeDps=;cT4kveyZgA1smSTyj87YHA=="
---

